Research and License Agreements between National Cheng Kung University Medical College and Novo Nordisk A/S

Published: May 15, 2012

TAINAN, Taiwan--(BUSINESS WIRE)--A southern Taiwan-based National Cheng Kung University (NCKU) research team led by Ming-Shi Chang, NCKU professor of the Department of Biochemistry and Molecular Biology, has discovered an anti-interleukin-20 (anti-IL-20) antibody, a potential new anti-osteoporosis and anti-rheumatoid arthritis drug, and agrees to license selected intellectual property and transfer certain technology to Novo Nordisk A/S, a Danish-based pharmaceutical company for a total payment of US$ 13.3 million in case of a successful completion of the project.

Back to news